Bionano Genomics, Inc. (BNGO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 6,733 | 6,457 | 6,073 | 7,771 |
| Selling, general and administrative | 8,346 | 9,033 | 9,464 | 11,557 |
| Restructuring costs | - | - | 1,770 | 1,215 |
| Research and development | 2,931 | 2,370 | 4,717 | 6,831 |
| Intangible assets and other long-lived assets impairment | - | - | 19,504 | - |
| Total operating expenses | 11,277 | 11,403 | 35,455 | 19,603 |
| Product | 3,150 | - | - | - |
| Product And Service Other | 106 | - | - | - |
| Total cost of revenue | 3,256 | 3,519 | 14,519 | 5,186 |
| Loss from operations | -7,800 | -8,465 | -43,901 | -17,018 |
| Other income (expense) | 676 | 5,080 | -697 | 363 |
| Interest income | 277 | 290 | 376 | 457 |
| Total other income (expense) | 953 | 5,370 | -321 | 820 |
| Loss before income taxes | -6,847 | -3,095 | -44,222 | -16,198 |
| Provision for income taxes | 10 | 7 | 24 | 26 |
| Net loss | -6,857 | -3,102 | -44,246 | -16,224 |
| Net loss per share, basic (in dollars per share) | -1.99 | -1.15 | -0.52 | -0.24 |
| Net loss per share, diluted (in dollars per share) | -1.99 | -1.15 | -0.52 | -0.24 |
| Weighted-average common shares outstanding, basic (in shares) | 3,441,000 | 2,694,000 | 85,870,000 | 67,583,000 |
| Weighted-average common shares outstanding, diluted (in shares) | 3,441,000 | 2,694,000 | 85,870,000 | 67,583,000 |